---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000038"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-07-22T20:01:17+00:00"
generated_at: "2026-07-22T20:02:07.367251+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics CFO Keith Regnante resigns; Annita Tanini named interim CFO

## Summary
- CFO Keith Regnante resigns effective Aug 3, 2026, voluntarily with no disagreement over accounting or controls.
- Annita Tanini, Corporate Controller and VP Finance, appointed interim principal financial and accounting officer effective Aug 4, 2026.
- Tanini receives $302,300 base salary, 30% target bonus, and severance of 6 months base plus COBRA.
- Regnante receives only accrued salary and expenses; no additional severance.
- Company has commenced search for a permanent CFO.

## SEC filing metadata
- accession: 0001664710-26-000038
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-07-22T20:01:17+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000038/0001664710-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000038/kros-20260717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000038
- JSON: https://secwatch.observer/filing/0001664710-26-000038.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.